Literature DB >> 19004033

Vascular endothelial growth factor in rabbits during development of corticosteroid-induced osteonecrosis: a controlled experiment.

Tamon Kabata1, Tadami Matsumoto, Shinichi Yagishita, Tomohiko Wakayama, Shoichi Iseki, Katsuro Tomita.   

Abstract

OBJECTIVE: Vascular endothelial growth factor (VEGF) is an angiogenic promoter that is rapidly induced as a response to local hypoxia. We investigated VEGF expression in rabbits in a controlled experiment to clarify the onset of ischemic events in corticosteroid-induced osteonecrosis (ON).
METHODS: Ninety-nine mature Japanese white rabbits were divided into 6 treatment groups and an untreated control group. The treatment groups received a single intramuscular injection of 4 mg/kg methylprednisolone acetate; they were euthanized at different times, and tissue samples were obtained from their femora. We examined the development of ON and the expression of VEGF using histopathology, immunohistochemistry, Northern blot analysis, and Western blot analysis.
RESULTS: On histopathological examination, the earliest indication of ON was 5 days after the corticosteroid treatment. The frequency of ON occurrence reached a plateau at or after Week 1. VEGF expression was accompanied by the development of ON. VEGF-positive cells detected by immunohistochemistry were found among bone marrow cells, frequently located in the area surrounding ON, suggesting that VEGF production was switched on as a result of the ischemic events that cause ON. The level of VEGF-mRNA expression indicated by Northern blot analysis peaked at 3 days after the corticosteroid treatment and decreased gradually to the levels present in the control group at 7 days after treatment. Western blot analysis revealed VEGF protein production at 3 days after the corticosteroid treatments. Levels of VEGF expression 2 weeks or more after the corticosteroid treatment were almost the same as in the control group.
CONCLUSION: We observed early expression of VEGF in the cells around the corticosteroid-induced ON lesions in rabbits. These results suggest that the ischemic events that cause ON begin soon after the initial corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004033     DOI: 10.3899/jrheum.070838

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents.

Authors:  Olivier Mir; Romain Coriat; Thomas Gregory; Stanislas Ropert; Bertrand Billemont; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-02-24       Impact factor: 3.850

2.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Authors:  Jason Fangusaro; Sridharan Gururangan; Regina I Jakacki; Sue C Kaste; Stewart Goldman; Ian F Pollack; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Osteonecrosis of the femoral head: genetic basis.

Authors:  Tracy Wang; Bouziane Azeddine; Wayne Mah; Edward J Harvey; David Rosenblatt; Chantal Séguin
Journal:  Int Orthop       Date:  2018-10-17       Impact factor: 3.075

4.  Osteocytic cell necrosis is caused by a combination of glucocorticoid-induced Dickkopf-1 and hypoxia.

Authors:  Shusuke Ueda; Toru Ichiseki; Yasuo Yoshitomi; Hideto Yonekura; Yoshimichi Ueda; Ayumi Kaneuji; Tadami Matsumoto
Journal:  Med Mol Morphol       Date:  2014-05-13       Impact factor: 2.309

5.  Heme oxygenase-1 prevents glucocorticoid and hypoxia-induced apoptosis and necrosis of osteocyte-like cells.

Authors:  Hiroki Yamamoto; Masazumi Saito; Tsuyoshi Goto; Keiichiro Ueshima; Masashi Ishida; Shigeki Hayashi; Kazuya Ikoma; Osam Mazda; Toshikazu Kubo
Journal:  Med Mol Morphol       Date:  2019-01-31       Impact factor: 2.309

6.  Corticosteroid administration within 2 weeks after renal transplantation affects the incidence of femoral head osteonecrosis.

Authors:  Masazumi Saito; Keiichiro Ueshima; Mikihiro Fujioka; Masashi Ishida; Tsuyoshi Goto; Yuji Arai; Kazuya Ikoma; Hiroyoshi Fujiwara; Wakaba Fukushima; Toshikazu Kubo
Journal:  Acta Orthop       Date:  2014-04-30       Impact factor: 3.717

7.  Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.

Authors:  Sue C Kaste; Robert A Kaufman; Amar Gajjar; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

8.  The pathogenesis of nontraumatic osteonecrosis.

Authors:  Jesse Seamon; Thomas Keller; Jamal Saleh; Quanjun Cui
Journal:  Arthritis       Date:  2012-11-08

9.  Bone vascularization in normal and disease conditions.

Authors:  Christian Carulli; Massimo Innocenti; Maria Luisa Brandi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-26       Impact factor: 5.555

10.  Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head.

Authors:  Yuma Sakamoto; Takuaki Yamamoto; Nobuhiko Sugano; Daisuke Takahashi; Toshiyuki Watanabe; Takashi Atsumi; Junichi Nakamura; Yukiharu Hasegawa; Koichi Akashi; Ichiei Narita; Takeshi Miyamoto; Tsutomu Takeuchi; Katsunori Ikari; Koichi Amano; Atsuhiro Fujie; Toshikazu Kubo; Yoshifumi Tada; Ayumi Kaneuji; Hiroaki Nakamura; Tomoya Miyamura; Tamon Kabata; Ken Yamaji; Takahiro Okawa; Akihiro Sudo; Kenji Ohzono; Yoshiya Tanaka; Yuji Yasunaga; Shuichi Matsuda; Yuuki Imai; Masato Akiyama; Michiaki Kubo; Yoichiro Kamatani; Yukihide Iwamoto; Shiro Ikegawa
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.